Patents by Inventor Julien Hazemann

Julien Hazemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms
    Patent number: 10351560
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 16, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist, Markus Von Raumer
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 10301309
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 28, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • CRYSTALLINE FORMS
    Publication number: 20190047996
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Idorsia Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST, Markus VON RAUMER
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20180105520
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Azaindole acetic acid derivatives and their use as prostaglandin Dreceptor modulators
    Patent number: 9879006
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 30, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9850241
    Abstract: The present invention relates to azaindolle acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 26, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170129884
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 17, 2015
    Publication date: May 11, 2017
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170022196
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 26, 2017
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 8697869
    Abstract: The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I), wherein R1, R2 and R3 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 15, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Heinz Fretz, Julien Hazemann, Sylvia Richard-Bildstein, Romain Siegrist
  • 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20130065902
    Abstract: The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I), wherein R1, R2 and R3 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 21, 2011
    Publication date: March 14, 2013
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Heinz Fretz, Julien Hazemann, Sylvia Richard-Bildstein, Romain Siegrist
  • THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20110105491
    Abstract: The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 5, 2011
    Inventors: Hamed Aissaoui, Christoph Boss, Julien Hazemann, Ralf Koberstein, Romain Siegrist, Thierry Sifferlen